GenMark Diagnostics Stock News

GenMark Diagnostics, Inc (NASDAQ:GNMK) was the recipient of some unusual options trading on Thursday. Stock traders acquired 4,370 call options on the stock. This is an increase of approximately 411%

The Board of Directors of Mesa Biotech, announced today the appointment of Ingo Chakravarty as President and Chief Executive Officer (CEO), effective immediately.

The "COVID-19 Testing: Symptoms, Asymptomatic, and Serology for Immunity" report from Wintergreen Research, Inc has been added to ResearchAndMarkets.com's offering.

Co-Diagnostics has been the toast of Wall Street after it went from penny stock status to a revered coronavirus testing stock.

AQR Capital Management LLC decreased its position in GenMark Diagnostics, Inc (NASDAQ:GNMK) by 65.5% during the fourth quarter, Holdings Channel reports. The firm owned 43,420 shares of the medical eq

Goldman Sachs Group Inc. lowered its stake in shares of GenMark Diagnostics, Inc (NASDAQ:GNMK) by 9.4% during the fourth quarter, according to the company in its most recent disclosure with the Securi

We screen the Russell 2000 stocks to highlight the biggest winners in 2020. Several healthcare company stocks benefiting from the coronavirus pandemic are among

Zacks Investment Research upgraded shares of GenMark Diagnostics (NASDAQ:GNMK) from a hold rating to a buy rating in a research note released on Thursday, Zacks.com reports. Zacks Investment Research

Throughout my (lengthy) career on the sell side and buy side following the medical stocks, I have studied respected market technicians and strategists. Technica

Man Group plc lessened its holdings in GenMark Diagnostics, Inc (NASDAQ:GNMK) by 26.5% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm o

Credit Suisse AG lowered its position in shares of GenMark Diagnostics, Inc (NASDAQ:GNMK) by 29.6% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 29,429 share

GenMark Diagnostics (NASDAQ:GNMK) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Friday, Zacks.com reports. Accord

GenMark Diagnostics, Inc (NASDAQ:GNMK) traded up 2.3% during mid-day trading on Thursday . The company traded as high as $6.23 and last traded at $6.18, 181,108 shares traded hands during mid-day trad

GenMark Diagnostics, Inc (NASDAQ:GNMK) shares saw strong trading volume on Wednesday . 8,451,996 shares were traded during trading, an increase of 350% from the previous session’s volume of 1,878,54